Edgewise Therapeutics, Inc. (EWTX)

Edgewise Therapeutics' stock has experienced an upward trajectory, with its price ranging from approximately $11.42 to $30.03 over the past year. Shares rallied strongly after the FDA assigned Orphan and Rare Pediatric designations to EDG-5506. Investors are particularly interested in the company's lead product candidate, EDG-5506, which is in Phase II clinical trials, and EDG-7500, which is in Phase I trials. In December 2025, the stock rose following a positive update on its hypertrophic cardiomyopathy (HCM) drug. There have been instances of insider selling, with a director selling a significant number of shares in January 2026, and insider buying by a director in November 2025 and by Orbimed Advisors LLC in April 2025. The company provided corporate updates and highlighted priorities for 2026 in January 2026.

Information regarding specific demand seasonality for Edgewise Therapeutics, Inc.'s products and services is not explicitly detailed in the provided search results. As a clinical-stage biopharmaceutical company, its revenue generation is currently limited, and its focus is on research and development rather than commercial product sales. Therefore, traditional demand seasonality patterns for commercial products may not directly apply at this stage. Analysis of historical stock returns can sometimes reveal seasonal patterns, though specific details for EWTX require further access to specialized financial data.

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for severe, rare muscle disorders and serious cardiac conditions. The company leverages its expertise in muscle biology and small molecule drug discovery to build a proprietary, muscle-focused platform. Its major product candidates include EDG-5506 (sevasemten), an orally administered small molecule in Phase II clinical trials for dystrophinopathies, and EDG-7500, a novel cardiac sarcomere modulator in Phase I/II clinical development for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders. The company focuses on identifying and modulating specific protein targets involved in muscle health and disease to restore normal cellular function and improve patient outcomes.

Edgewise Therapeutics, Inc. is headquartered in Boulder, Colorado, and Cambridge, Massachusetts. While it primarily operates in the United States, the company is actively preparing for global clinical trials and seeking collaborations and partnerships to broaden patient access internationally.

Edgewise Therapeutics generally holds a positive brand reputation within the investment community, particularly among analysts. The company has received a consensus rating of "Moderate Buy" from analysts, with a significant number of buy ratings. This positive sentiment is largely driven by the promising progress of its lead drug candidates in clinical trials for serious muscle disorders. The company's commitment to scientific rigor, patient-centricity, and strategic partnerships also underpins its reputation.

Approximately 86.70% to 95.28% of Edgewise Therapeutics, Inc.'s stock is owned by institutional investors, including Orbimed Advisors Llc, Ra Capital Management, L.p., and Baker Bros. Advisors Lp. Individual insiders own approximately 0.522% to 1.38% of the stock, while public companies and individual investors hold around 3.33% to 8.58%.